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Abstract
Introduction: Atacicept is a soluble, fully human, recombinant fusion protein that inhibits B cell-stimulating factors
APRIL (a proliferation-inducing ligand) and BLyS (B-lymphocyte stimulator). The APRIL- LN study aimed to evaluate
the efficacy and safety of atacicept in patients with active lupus nephritis (LN), receiving newly initiated
corticosteroids (CS) and mycophenolate mofetil (MMF).
Methods: This was a randomized, double-blind, placebo-controlled Phase II/III, 52-week study. At screening (Day
-14), patients initiated high-dose CS (the lesser of 0.8 mg/kg/day or 60 mg/day prednisone) and MMF (1 g daily,
increased by 1 g/day each week to 3 g daily). From Day 1, atacicept (150 mg, subcutaneously, twice weekly for 4
weeks, then weekly) was initiated with MMF along with a tapered dose of CS.
Results: The trial was terminated after the enrollment of six patients, due to an unexpected decline in serum
immunoglobulin G (IgG) and the occurrence of serious infections. Efficacy was thus not evaluated. By Day 1, serum
IgG levels had declined substantially in patients then randomized to atacicept (n = 4) compared with placebo (n =
2). Patients receiving atacicept also had more severe proteinuria on Day -14 than those on placebo. Lymphocyte
counts were low at screening in all patients. IgG decline continued following initiation (Day 1) of atacicept. Three
atacicept-treated patients developed serum IgG below the protocol-defined discontinuation threshold of 3 g/l, two
of whom developed serious pneumonia.
Conclusions: Future studies are needed to characterize the safety, efficacy, and pharmacodynamic response of
atacicept in LN patients.
Trial Registration: ClinicalTrials.gov: NCT00573157
Keywords: atacicept, clinical trial, immunoglobulin, lupus nephritis, mycophenolate mofetil, nephrotic-range
proteinuria
Introduction
Current treatments for lupus nephritis (LN), a severe
complication of systemic lupus erythematosus (SLE),
may be associated with significant toxicity (for example,
infertility, infection, malignancy), and complete remis-
sion rates remain low [1]. The pathogenesis of LN is
complex and involves immune-mediated mechanisms,
including autoantibody production and immune
complex deposition in the kidney [2]. Atacicept is a
soluble, fully human, recombinant fusion protein that
inhibits the B cell-stimulating factors APRIL (a prolifera-
tion-inducing ligand) and BLyS (B-lymphocyte stimula-
tor). APRIL and BLyS levels are altered in some
autoimmune diseases associated with increased autoanti-
body production [3]. A Phase II/III randomized, double-
blind, placebo-controlled clinical trial was initiated to
evaluate the efficacy and safety of atacicept in patients
with active LN who were receiving newly initiated
immunosuppressive therapy with corticosteroids (CS)
and mycophenolate mofetil (MMF). This trial was
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terminated after only six patients had been enrolled, as a
result of unexpected falls in serum immunoglobulin G
(IgG) and the occurrence of serious infections. No effi-
cacy evaluation took place.
Materials and methods
Study design
On Study Day -14, patients commenced MMF (500 mg,
twice daily, orally) and prednisone/prednisone equiva-
lent (the lesser of 0.8 mg/kg/day or 60 mg/day, orally).
MMF dose was increased to 1,000 mg twice daily at Day
-7, thereafter up to a maximum of 1.5 g twice daily by
Day 1. Day -14 to Day 1 was defined as the screening
period. Patients fulfilling all entry criteria were rando-
mized (1:1) on Day 1 to placebo or atacicept, 150 mg
subcutaneously, twice weekly for 4 weeks, then 150 mg
weekly for a planned 48 weeks. The CS dose was to be
tapered starting at Week 5 by 5 mg/day/week, to 10
mg/day by Week 12. Assessments were scheduled post
Day 1 at Weeks 2 and 4, then every 4 weeks to Week
52. Following the discontinuation of the study drug
(completion of 52 weeks of treatment or early termina-
tion), follow-up visits were scheduled 4, 12 and 24
weeks after the last dose.
Patients
Key inclusion criteria were: SLE diagnosis satisfying ≥ 4
of the 11 American College of Rheumatology criteria
[4]; positive antinuclear antibody test (Hep-2 antinuclear
antibody ≥ 1:80) and/or antibodies against double-
stranded DNA ([anti-dsDNA] ≥ 30 IU/ml); renal biopsy
within the 12 months preceding study entry, with histo-
logical findings consistent with active LN (International
Society of Nephrology/Renal Pathology Society class III
or IV LN); active LN, defined by proteinuria (urine pro-
tein:creatinine ratio [UPr:Cr] > 1.0 mg/mg) and hema-
turia (> 10 red blood cells [RBCs]/high-powered field
[hpf] with or without RBC casts): all other causes of
hematuria of non-glomerular origin were excluded. Key
exclusion criteria were: renal disease unrelated to SLE;
calculated glomerular filtration rate ([GFR] based on the
Modification of Diet in Renal Disease equation) ≤ 30
ml/min/1.73 m2 at screening; comorbidities requiring
CS; progressive disease (25% decrease in GFR or dou-
bling of UPr:Cr between screening and randomization).
The Institutional Review Board or Ethics Committee at
each center approved the study; written informed con-
sent was obtained from each patient or their legal repre-
sentative, according to the Declaration of Helsinki.
Criteria for discontinuation
Key criteria for discontinuation were: 25% decrease in
calculated GFR or doubling of UPr:Cr compared with
baseline; IgG level < 3 g/L; minimal or no improvement
in renal parameters at Week 24.
Results
Patient disposition and safety results
At the time of termination, six patients from four cen-
ters in the US had been randomized: two to receive pla-
cebo and four to receive atacicept (Table 1). Four
patients were women and two men; the age range was
18 to 54 years.
The courses of the four atacicept-treated patients are
described here. Three patients developed serum IgG
levels below the protocol-defined discontinuation criter-
ion. Patient #3 had an IgG level of 2.9 g/l on Day 29
and developed Haemophilus influenzae pneumonia com-
plicated by empyema, septicemia and pneumothorax;
treatment was discontinued on Day 30. Patient #13 had
an IgG level of 2.5 g/l on Day 30; treatment was discon-
tinued on Day 33 and the patient was diagnosed with
Legionella pneumophila pneumonia on Day 34. Patient
#14 had an IgG of 2.5 g/l and was discontinued on Day
18. At Week 12 of the safety follow-up period, this
patient developed Bacillus bacteremia. Patient #5 had
atacicept administered until Day 230, when the study
was discontinued. Her IgG level decreased from a base-
line of 20.1 to 4.7 g/l at Week 12, and then gradually
increased to 6.9 g/l at approximately Week 34 (when
atacicept was terminated along with the study).
In both placebo-treated patients, IgG levels fell
between Days 1 and 15, declining to nadirs at Weeks 4
and 8 above the lower limit of normal [LLN] (11.9 g/l in
Patient #2; 10.2 g/l in Patient #8), before gradually
increasing. Patient #2 discontinued study participation
due to leukocytoclastic vasculitis, 148 days post rando-
mization. Patient #8 continued until the time of study
termination, 85 days post randomization.
The study was terminated early as a result of the
above safety events and, thus, none of the patients
reached full treatment to Week 52. Enrollment ceased
and study drug administration stopped in all patients.
All patients completed a 24-week post-treatment follow-
up period. Table 1 provides demographic and disease
history characteristics, study treatment duration, and
reasons for discontinuation.
Laboratory measurements
Immunoglobulin levels across the study period are
shown in Figure 1. Serum IgG levels were normal or
elevated in all patients at screening. Following the initia-
tion of MMF and CS, a marked reduction in IgG (up to
57%) was observed by Day 1 (Table 2; Figure 1A). The
decreases were largest in those patients who were subse-
quently randomized to atacicept. Serum IgG levels
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continued to decline between Days 1 and 14, by up to
47% versus Day 1 and 72% versus Day -14 (Table 2).
Neither IgA nor IgM levels showed a consistent
decrease among enrolled patients (Table 2; Figures 1B,
C).
At screening, the patients subsequently randomized to
atacicept presented with more severe proteinuria (UPr:
Cr ≥ 3.0 versus ≤ 2.3 mg/mg) and a lower mean GFR
(52.1 versus 76.1 ml/min/1.73 m2) compared with those
who were randomized to placebo on Day 1. Baseline
GFR was particularly low in Patients #13 and #14, and
remained so on Days 1 and 14. Whereas UPr:Cr had
fallen below 1.0 mg/mg in Patient #2 on Days 1 and 14,
and in Patient #8 on Day 14 (Day 1 reading unavailable),
it remained high on Days 1 and 14 in patients rando-
mized to atacicept (range 5.6 to 18.0 mg/mg, with the
exception of a value of 1.0 mg/mg in Patient #5 on Day
1). At the end of the study period, both placebo-treated
and two atacicept-treated patients (Patients #5 and #13)
had UPr:Cr ratios that were lower than baseline values.
In a third atacicept-treated patient (Patient #3), the ratio
was approximately the same as at baseline, and in
Patient #14 it was higher than at baseline.
Patients entered the study with wide variations in
counts of white blood cells (WBCs), absolute neutro-
phils, and absolute lymphocytes (Table 3). During the
study, WBCs fluctuated in all patients but were within
the normal range by the 24-week follow-up visit in all
except Patient #5. Neutrophilia was common at screen-
ing and Day 1. Lymphocyte concentrations at screening
were below or at the lower end of the reference range
(0.9 to 4.3 × 109/l) in all patients (Table 3). In Patients
#3 and #13, lymphocyte counts declined from a baseline
(Day -14) level within the reference range (0.9 and 1.5 ×
109/l, respectively) to Grade 2 lymphopenia by Day 1
(0.7 × 109/l in both). After addition of atacicept, lym-
phocytes continued to decline in both patients, with
Grade 3 lymphopenia developing in Patient #3 on Day
29 (0.5 × 109/l), coincident with H. influenzae pneumo-
nia, and in Patient #13 on Days 15 and 30, the latter
(0.5 × 109/l) coincident with development of L. pneumo-
phila pneumonia. CD4+ counts (not measured at screen-
ing) were also low on Day 1, in all patients measured.
On Day 1, one placebo- and three atacicept-treated
patients had C3 levels below the LLN (Table 3). C3 and
C4 levels rose during treatment in all patients, but
started and remained below the LLN in Patient #14 (on
atacicept), and were below the LLN at Day 1 and at end
of treatment in Patient #2 (on placebo), having risen
above the LLN during treatment. C3 levels were within
the normal range at end-of-treatment assessments in
the remaining three patients on atacicept and one on
placebo (Table 3).
Discussion
This study was terminated as a result of the emergence
of unexpected, profound and rapid declines in IgG levels
and the occurrence of serious infections. Several factors
complicate the interpretation of the results. First, the
large decreases in IgG began with initiation of MMF
and high-dose CS two weeks before the initiation of ata-
cicept (and continued IgG decrease). This was unex-
pected: to the authors’ knowledge, such large decreases
in IgG levels do not appear to have been reported in
previous publications discussing MMF and/or CS treat-
ment in patients with LN [5,6]. However, high-dose CS
therapy has been reported to decrease IgG synthesis: in
a patient with SLE, serum IgG levels fell from 1,580 to
630 mg/100 ml following 6 weeks’ CS treatment (60
mg/day) [7]. In addition, hypogammaglobulinemia has
been reported in approximately half of renal transplant
patients receiving MMF in combination with CS [8]. It
is of interest to note that an increased risk of infection
has been observed in other LN studies during the
Table 1 Demographic characteristics, disease history, duration on study and reasons for discontinuation
Patient # Race Disease historya Prior
therapy







Prior renal flare MMF CTX
2 African American 38 < 1 - - - 148 Leukocytoclastic vasculitis
8
3
Caucasian 46 38 + + - 85 Study termination
African American < 1 < 1 - - - 29 H. influenzae pneumonia,
IgG < 3 g/l
5 African American 3 < 1 - - - 230 Study termination
13 African American 52 52 + + + 31 IgG < 3 g/lb
14 Asian 32 < 1 + + + 18 IgG < 3 g/l
Patients’ mean (SD) height and weight were 169.3 (9.7) cm and 83.3 (20.8) kg, respectively. Patients #2 and #8 randomized to placebo; Patients #3, #5, #13
and#14 randomized to atacicept 150 mg subcutaneously twice weekly (4 weeks), then 150 mg weekly (48 weeks). aDisease history: time between SLE/LN
diagnosis and consent. All patients had Class IV renal disease. bPatient #13 diagnosed with severe Legionella pneumonia on Day 34, 1 day after study
discontinuation. CTX, cyclophosphamide; IgG, immunoglobulin G; LN, lupus nephritis; MMF, mycophenolate mofetil; SLE, systemic lupus erythematosus.
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Figure 1 Immunoglobulin (Ig) levels in all six patients, across the study period. A) IgG, reference range (RR) 5.65 to 17.65 g/l, < 3 g/l
represented study discontinuation threshold; B) IgA, RR 0.7 to 4 g/l; C) IgM, RR 0.4 to 2.3 g/l. IgA and IgM were not measured during the
screening period (Days-14 to 1). Discontinuation days were not necessarily scheduled follow-up days. LLN, lower limit of normal; ULN, upper
limit of normal.
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induction phase with MMF and high-dose CS, compared
with the maintenance phase [9,10]. The results reported
here raise the possibility that this increased risk may be
associated with severe hypogammaglobulinemia.
A second factor is that, by chance, those patients who
were subsequently randomized to atacicept had higher
proteinuria at screening (and through to Day 14) than
those subsequently randomized to placebo, and all ataci-
cept-randomized patients had UPr:Cr ratios ≥ 3.0 mg/
mg at screening. This could have had a significant
impact on the extent of IgG decrease. The magnitude of
the decrease (up to 57% in the two weeks prior to





Day 1 Day 14
























(g/l) (g/l) (g/l) (%)
2 73.5L 1.6 16.3 68.4L 0.2 1.9 1.0 16.3 0 45.3L1, a 0.1a 2.0a 0.8a 15.1a -7.4
8 78.7 2.3 14.2 76.3 N/A 2.9 0.3L 13.9 -2.1 88.8a 0.8a 2.7a 0.3L,
a
11.1a -20.1
3 73.4L 8.2 16.3 81.6 5.6 4.5 1.2 13.0 -20.3 72.2L 8.1a 2.3a 0.7a 6.5a -49.7
5 74.5L 3.0 20.1 89.0 1.0 6.3 1.2 14.3 -28.9 69.7L, b 7.1 5.4b 1.1b 10.9b -23.8
















Patients #2 and #8 randomized to placebo; Patients #3, #5, #13 and #14 randomized to atacicept 150 mg subcutaneously twice weekly (4 weeks), then 150 mg
weekly (48 weeks). *IgA and IgM levels not recorded at screening; GFR, glomerular filtration rate; Ig, immunoglobulin; UPr:Cr, urine protein:creatinine ratio.
Values > ULN indicated in italics; LValues < LLN with (Grade 1 to 4), where applicable; Ig reference ranges: IgA, 0.7 to 4.0 g/l; IgM, 0.4 to 2.3 g/l; IgG, 5.7 to 17.6 g/
l. aMeasured Day 15; bMeasured Day 13; cMeasured Day -18; dMeasured Day 18. †GFR > 30 ml/min/1.73 m2 on repeat testing.
Table 3 Hematologic and serologic parameters Day -14 to end of treatment (EOT)











Day 1 Day 14 (± 1) EOT Day
-14
Day 1 Day 14 (± 1) EOT Day
-14
Day 1 Day 14 (± 1) EOT
2 11.2 6.0 8.3 3.8 1.7 1.6 1.7 2.0 8.9 4.1 6.4 1.6L1
8 6.3 15.1 12.4 8.1 0.8L2 0.9 1.3 1.0 5.0 13.7 10.6 7.0
3 5.7 11.1 8.1 4.7 0.9 0.7L2 0.5L2 0.2L3 4.4 10.1 7.4 4.3
5 2.8L2 15.6 N/A N/A 1.0 3.4 N/A N/A 1.6L1 10.6 N/A N/A
13 14.7 5.6 8.5 7.6 1.5 0.7L2 0.5L3 0.7L2 13.1 4.7 7.8 6.5






< 30.0, negative; 30-75, borderline; >
75, positive
Patient # Day 1 Day 28 (± 2) EOT Day 1 Day 14 (± 1) EOT Day
-14
Day 1 Day 14 (± 1) EOT
2 489 [25.8L] 1731 [34.1] 980 [44.6] 0.686L 0.904 0.721L 917.2 375.7 168.1 463.9
8 277L2 [23.5L]c 273L2 [29.7L] 195L3 [24.0L] 0.915 1.150 1.070 325.5 306.1 97.6 20.1
3 N/A 56L3 [13.7L] 45L4 [21.4L] 0.533L 0.800L 0.906 155.3 77.6 37.5 < 12.3
5 529 [22.1L] 809 [30.1L] 603 [46.8] 1.030 1.630 1.700 56.7 43.0 34.3 12.6
13 240L2 [38.7] 95L3 [23.8L] 163L3 [19.3L] 0.462L 0.717 0.909 87.5 26.0 13.0 12.7
14 135L3 [19.1L] N/A 158L3 [19.9L] 0.434L 0.541b 0.609L 349.6 88.1 28.8b 20.1
Patients #2 and #8 randomized to placebo; Patients #3, #5, #13 and #14 randomized to atacicept 150 mg subcutaneously twice weekly (4 weeks), then 150 mg
weekly (48 weeks). N/A, not available; RR, reference range. Values > ULN indicated in italics; LValues < LLN, with Grade (1 to 4), where applicable. aMeasured Day
-10; bMeasured Day 18; cMeasured Day 4.
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atacicept initiation) suggests that the mechanism(s) for
this decrease included an abnormally high excretion of
IgG as well as a decrease in IgG production (associated
with MMF and CS administration). This hypothesis is
supported by the fact that proteinuria levels > 2 g/day
are associated with the excretion of large proteins in the
urine, which could include IgG. The high levels of pro-
teinuria may have also affected the pharmacokinetics of
atacicept, since atacicept is a protein that may be
secreted in the urine in the setting of heavy proteinuria.
Baseline GFR was, however, lower in the patients who
were randomized to atacicept and, thus, the net effect of
higher proteinuria and reduced GFR on atacicept secre-
tion is not known.
In this study, lymphopenia and low CD4+ counts were
observed in both patients who developed serious pneu-
monia. Lymphocyte counts were low in all patients at
baseline, before MMF initiation; this could be due to
active lupus, as well as CS use. Indeed, lymphopenia and
low IgG levels may each have been related to CS use,
but were not necessarily related to each other. In clinical
studies of atacicept to date, including healthy volunteers
and patients with rheumatoid arthritis or generalized
SLE, no association between atacicept and reduced T-
cell, neutrophil or lymphocyte counts has been observed
[11-13].
Atacicept inhibits both APRIL and BLyS, and has been
shown to decrease levels of IgG, IgM and IgA, as well as
naive B cells and plasma cells [11-13]. In Phase II stu-
dies in patients with rheumatoid arthritis, atacicept 150
mg was associated with median IgG decreases of
approximately 30%. This decrease was near maximal by
12 to 16 weeks, no patients on atacicept had IgG levels
below 3 g/l, and the rate of serious infections was not
notably increased [11-13]. The results reported here are
substantially different, suggesting that the biology of the
disease likely contributed to this effect, and requires
further study; the results may reflect alterations in pro-
teins as yet unidentified in active LN.
Conclusions
Increased risk of serious infections and large decreases
in IgG were observed in patients with active LN and
nephrotic-range proteinuria, in whom MMF and high-
dose CS were initiated two weeks prior to atacicept (150
mg, twice weekly). Future studies will be needed to
characterize the pharmacokinetic-pharmacodynamic,
safety and efficacy profiles of atacicept in LN patients.
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